

Expression of nitrile hydratases in a two-vector expression system

The present invention relates to an expression system for
5 preparing nitrile hydratases. Nitrile hydratases consist of
different subunits. The present system makes it possible to
prepare nitrile hydratases in a manner superior to that of
the prior art by expressing the nucleic acid sequences
encoding these subunits separately on separate plasmids.


10

The amide and carboxylic acid structural classes are
becoming increasingly important as precursors of fine
chemicals. Special aminoamides and (proteinogenic and
nonproteinogenic) amino acids are key intermediates for
15 synthesizing pharmaceutical and agrochemical products as
well as in the foodstuff field. Enantiomerically pure amides
and amino acids, in particular, play a role which is
becoming ever more important in the abovementioned
application fields.

20

Aminonitrile precursors, as are required for preparing the
abovementioned compound classes, can readily be obtained in
racemic form using the Strecker synthesis. The nitriles
which are obtained in this way can then be converted by
25 means of chemical or enzymic hydrolysis into the
corresponding amides and carboxylic acids.

Three enzymes which can participate in the enzymic
hydrolysis of nitriles are known. Nitrilases convert a
30 nitrile function directly into the acid, whereas nitrile
hydratases (E.C. 4.2.1.84) form the corresponding amide
under these circumstances. This latter can finally be
converted into the corresponding carboxylic acid by an
amidase (E.C. 3.5.1.4) (scheme 1).



Scheme 1:

5 Hydrolyzing nitriles to the corresponding amides and acids using isolated enzymes or whole-cell catalysts helps to save large quantities of salt which would otherwise accrue in connection with the neutralization step following the chemical hydrolysis of nitriles. For this reason, the
 10 enzymic hydrolysis of nitriles to, for example, aminoamides and/or amino acids constitutes a more sustainable production process.

In their active form, nitrile hydratases consist of 2
 15 nonhomologous α - and β -subunits. These subunits form heterodimers and tetramers, while decamers have even been demonstrated in the case of *Rhodococcus rhodochrous* J1. While the α - and β -subunits are of approximately the same size, they are otherwise in no way similar to each other.
 20 Nitrile hydratases are metalloproteins which contain Fe³⁺ or Co³⁺ (Bunch A.W. (1998), Nitriles, in: Biotechnology Volume 8a, Biotransformations I, Chapter 6, Eds.: Rehm HJ, Reed G, Wiley-VCH, p. 277-324; Shearer J, Kung IY, Lovell S, Kaminsky W, Kovacs JA (2001) Why is there a "inert" metal
 25 center in the active site of nitrile hydratase? Reactivity and ligand dissociation from a five-coordinate Co(III) nitrile hydratase model. J Am Chem Soc 123: 463-468; Kobayashi M, Shimizu S (2000) Nitrile hydrolases. Current Opinion in Chemical Biology 4: 95-102).

One of the greatest challenges to date has been that of heterologously preparing nitrile hydratases in a suitable host, preferably in *E. coli*. This Gram-negative bacterium is known for its ability to express heterologous proteins at high rates. Another advantage is the yield of biomass in high-cell-density fermentations using *E. coli*. In this connection, it is possible to achieve productivities of more than 100 g of dry biomass (DBM) in from 24 to 44 hours (Lee SY (1996) High cell-density culture of *Escherichia coli*. TIBTECH 14:98-105; Riesenbergr D, Guthke R (1999) High-cell-density cultivation of microorganisms. Appl Microbiol Biotechnol 51:422-430).

Most of the sequences for the nitrile hydratase α - and β -subunits are known from the genus *Rhodococcus*. However, it is precisely this genus whose nitrile hydratases have thus far only been expressed in *E. coli* with particular difficulty (Ikehata O, Nishiyama M, Horinouchi S, Beppu T (1989) Primary structure of nitrile hydratase deduced from the nucleotide sequence of a *Rhodococcus* species and its expression in *Escherichia coli*. Eur J Biochem 181: 563-570).

The literature describes one-vector systems for expressing nitrile hydratases, the specific activities of which systems lie between 4.2 and 12.2 U/mg of total protein in the case of codependent *R. rhodochrous* J1 nitrile hydratases (Kobayasjhi M, Nishiyama M, Nagasawa T, Horinouchi S, Beppu T, Yamada H (1991) Cloning, nucleotide sequence and expression in *Escherichia coli* of two cobalt-containing nitrile hydratase genes from *Rhodococcus rhodochrous*. Biochim Biophys Acta 1129: 23-33) and 452 U/mg of total protein in the case of an iron-dependent *Rhodococcus spec.* N-771 nitrile hydratase (Njori M, Yohda M, Odaka M, Matsushita Y, Tsujimura M, Yoshida T, Dohmae N, Takio K Endo I (1999) Functional expression of Nitrile hydratases in *E. coli*: Requirement of a nitrile hydratase activator and a post-translational modification of a ligand cysteine. J

Biochem 125: 696-704), which corresponds roughly to approx. 248 U/mg of DBM (dry biomass) (calculation in accordance with Goodsell DS (1991) Inside a cell. TIBS 16: 203-206). Interestingly, it was not possible to reproduce the latter
5 activity with nitrile hydratases from *R. erythropolis*, which is closely related to *Rhodococcus spec.* N-711, using similar vector systems and dispositions of the structural genes. There was, therefore, still a need for processes and systems which permit the enzymes under consideration to be made
10 available in a manner which is adequate for industrial scale preparations.

The skilled person is already familiar with the use of two-vector expression systems for heterologously expressing
15 recombinant proteins in *E. coli*, for example for forming the motor protein kinesin (Skowronek K, Kasprzak A (2002) A two-plasmid system for independent genetic manipulation of subunits of homodimeric proteins and selective isolation of chimeric dimers. Analytical Biochemistry 300: 185-191), the
20 plasminogen proactivator streptokinase (Yazdani SS, Mukherjee KJ (2002) Continuous-culture studies on the stability and expression of recombinant streptokinase in *Escherichia coli*; stability and expression of streptokinase in continuous culture. Bioprocess and Biosystems Engineering
25 24(6): 341-346), the complex of two human proteins (hematopoietic cell tyrosine phosphatase and mitogen protein kinase; Kholod N, Mustelin T (2001) Novel vectors for co-expression of two proteins in *E. coli*. 31: 322-328) or the human CKMB creatine kinase (WO95/12662).

30 However, no heteromeric enzymes, such as the nitrile hydratases, which are used as biocatalysts in the chemical industry have thus far been expressed using such a system.

35 The object was, therefore, to develop an expression system which makes it possible to efficiently express both cobalt-dependent and iron-dependent nitrile hydratases actively in

E. coli. In particular, the system according to the invention should be able to make the enzymes under consideration available at a rate of expression which is higher, and, where appropriate, in forms which are more stable, than in the case of the prior art in order, in this way, to make the use of these enzymes on an industrial scale advantageous from ecological and economic points of view.

These objects, and other objects which are not specified in detail but which ensue in an obvious manner from the prior art, are achieved by specifying an expression system having the features of the present claim 1. Claims 2 to 8 relate to preferred embodiments of the expression system according to the invention. Claims 9 and 10 are directed towards processes for preparing nitrile hydratases and/or (amino)carboxylic acids or (amino)carboxamides. Claim 11 protects a host organism which is equipped with the expression system.

The set object is achieved, extremely advantageously and nonetheless entirely surprisingly, by, in the case of an expression system for simultaneously expressing the nucleic acid sequences encoding the different subunits of a nitrile hydratase, the expression system possessing in each case at least one plasmid containing at least one nucleic acid sequence encoding the respective subunit. Using the proposed expression system, it is possible to heterologously express the nucleic acid sequences under consideration in a manner which is adequate for industrial scale preparations. In this connection, it may be particularly surprising that simply expressing the nucleic acid sequences encoding the corresponding nitrile hydratase subunits, which nucleic acid sequences are in fact organized in one operon, separately on different plasmids contributes to increasing the activity of the resulting nitrile hydratases by a factor of > 8 as compared with the "normal" expression. It was not possible to deduce this in an obvious manner from the prior art.

The expression system according to the invention can be used in all the host organisms which the skilled person takes into consideration for the present purpose. Microorganisms which are to be mentioned in this regard are organisms such as yeast, such as *Hansenula polymorpha*, *Pichia sp.* and *Saccharomyces cerevisiae*, prokaryotes, such as *E. coli* and *Bacillus subtilis*, or eukaryotes, such as mammalian cells, insect cells or plant cells. Host organisms into which plasmids containing the nucleic acid sequences can be cloned are used for replicating and isolating a sufficient quantity of the recombinant enzyme. The methods used for this purpose are well known to the skilled person (Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York). Preference is given to using *E. coli* strains for this purpose. The following are very particularly preferred: *E. coli* XL1 Blue, NM 522, JM101, JM109, JM105, RR1, DH5 α , TOP 10-, HB101, BL21 codon plus, BL21 (DE3) codon plus, BL21, BL21 (DE3) and MM294. Plasmids which are preferably used to clone the gene construct containing the nucleic acid according to the invention into the host organism are likewise known to the skilled person (see also PCT/EP03/07148; see below). Very particular preference is given to an expression system which is present in *E. coli* BL21 as the host.

Promoters are DNA sequence regions from which transcription of a gene or operon is controlled. The promoters which are particularly advantageous for implementing the invention and which are to be used, in particular, in *E. coli* are known to the skilled person (Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York). It has now proved to be advantageous if the expression of the nucleic acid sequences encoding the subunits is in each case under the control of the same promoter so that the nucleic

acid sequences encoding the subunits can be expressed at a rate which is as identical as possible. Suitable promoters can be selected from the group T7, lac, tac, trp, ara or rhamnose-inducible. Other promoters are mentioned in
5 (Cantrell, SA (2003) Vectors for the expression of recombinant proteins in E. coli. Methods in Molecular biology 235: 257-275; Sawers, G; Jarsch, M (1996) Alternative principles for the production of recombinant proteins in Escherichia coli. Applied Microbiology and
10 Biotechnology 46(1): 1-9). Very particular preference is given to using the T7 promoter in the expression system according to the invention (Studier, W.F.; Rosenberg A.H.; Dunn J.J.; Dubendorff J.W.; (1990), Use of the T7 RNA polymerase to direct expression of cloned genes, Methods
15 Enzymol. 185, 61-89; or brochures supplied by the companies Novagen or Promega).

It has been found to be useful, for the ability of the expression system according to the invention to function,
20 for particular nucleic acid sequences, which encode peptide sequences known to be helper proteins and whose functions have previously to a large extent been unknown, to be present on the corresponding plasmids. These sequences are known to the skilled person in regard to producing active
25 nitrile hydratases (Nojiri M; Yohda M; Odaka M; Matsushita Y; Tsujimura M; Yoshida T; Dohmae N; Takio K; Endo I (1999) Functional expression of nitrile hydratase in Escherichia coli: requirement of a nitrile hydratase activator and post-translational modification of a ligand cysteine. Journal of
30 biochemistry 125(4): 696-704). Very particular preference is given to an expression system in which at least one nucleic acid sequence encoding such a helper protein, in particular the p47K protein (Seq. ID No. 33) or the p12K protein (Seq. ID No. 31), is present per plasmid set employed. In this
35 connection, a plasmid set denotes the plasmids which are required in accordance with the invention for constructing an active nitrile hydratase.

As explained in detail at the outset, nitrile hydratases are known from a variety of organisms (see also PCT/EP04/00338; Dissertation, see above). However, preference is given to using, in the expression system according to the invention, those nucleic acid sequences which encode nitrile hydratase subunits which have their origin in nitrile hydratases derived from *Rhodococcus* strains. In this connection, the nucleic acid sequences which are employed can be altered, as compared with the original sequences from *Rhodococcus*, by means of mutagenesis on a chemical or molecular biological basis. In this connection, particular consideration is given to those nucleic acid sequences which encode subunits which are improved, as compared with the wild-type sequences, in regard to activity and/or selectivity and/or stability. According to the invention, the improvement in the activity and/or selectivity and/or stability denotes that the enzymes under consideration are more active and/or more selective or less selective, or more stable under the reaction conditions employed. While the activity and the stability of the enzymes should naturally, for the industrial application, be as high as possible, the selectivity is considered to be improved when either the substrate selectivity decreases but the enantioselectivity of the enzymes is increased.

The skilled person is sufficiently familiar with the procedure for using mutagenesis methods to improve the nucleic acid sequences according to the invention or the polypeptides which they encode. The mutagenesis methods which are suitable are any methods which are available to the skilled person for this purpose. In particular, these methods are saturation mutagenesis, random mutagenesis, in-vitro recombination methods and site-directed mutagenesis (Eigen, M. and Gardiner, W. (1984), Evolutionary molecular engineering based on RNA replication, Pure Appl. Chem. 56, 967-978; Chen, K. and Arnold, F. (1991), Enzyme engineering for nonaqueous solvents: random mutagenesis to enhance activity of subtilisin E in polar organic media.

Bio/Technology 9, 1073-1077; Horwitz, M. and Loeb, L. (1986), Promoters Selected From Random DNA-Sequences, Proc Natl Acad Sci USA 83, 7405-7409; Dube, D. and L. Loeb (1989), Mutants Generated By The Insertion of Random Oligonucleotides Into The Active-Site of The Beta-Lactamase Gene, Biochemistry 28, 5703-5707; Stemmer, P.C. (1994), Rapid evolution of a protein *in vitro* by DNA shuffling, Nature 370, 389-391 and Stemmer, P.C. (1994), DNA shuffling by random fragmentation and reassembly: *In vitro* recombination for molecular evolution. Proc Natl Acad Sci USA 91, 10747-10751).

Particular preference is given to the nucleic acid sequences encoding the nitrile hydratase subunits being derived from Rhodococcus strains, in particular *R. erythropolis* 870-AN019.

In another preferred embodiment, the nucleic acid sequences employed are altered such that they correspond particularly well to the *E. coli* codon usage. It has been found that the yields of the enzymes obtained can be increased still further in proportion to the extent to which the codon usage of the gene to be expressed corresponds to that of *E. coli*. Particular preference is therefore given to modifying the nucleic acid sequences which encode the nitrile hydratase subunits in conformity with the *E. coli* codon usage. "Codon usage" is understood as being the fact that different organisms use different base triplets, which encode the same amino acids (degeneracy of the genetic code) to differing extents.

In principle, the plasmids or vectors which can be used are any types which are available to the skilled person for this purpose. These plasmids and vectors are listed, for example, in Studier and coworkers (Studier, W.F.; Rosenberg A.H.; Dunn J.J.; Dubendorff J.W.; (1990), Use of the T7 RNA polymerase to direct expression of cloned genes, Methods Enzymol. 185, 61-89) or the brochures supplied by the

companies Novagen, Promega, New England Biolabs, Clontech and Gibco BRL. Other preferred plasmids and vectors can be found in: Glover, D.M. (1985), DNA cloning: a practical approach, Vol. I-III, IRL Press Ltd., Oxford; Rodriguez, R.L. and Denhardt, D.T. (eds) (1988), Vectors: a survey of molecular cloning vectors and their uses, 179-204, Butterworth, Stoneham; Goedeel, D.V. (1990), Systems for heterologous gene expression, Methods Enzymol. 185, 3-7; Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York. Plasmids which can be used to clone the gene constructs containing the nucleic acid sequences encoding the subunits into the host organism in a very preferred manner are: pUC18/19 (Roche Biochemicals), pKK-177-3H (Roche Biochemicals), pBTac2 (Roche Biochemicals), pKK223-3 (Amersham Pharmacia Biotech), pKK-233-3 (Stratagene) and pET (Novagen). Very particular preference is given to an expression system which is based on plasmids belonging to the pET series. Extreme preference is given to using plasmids of the same series for expressing both the nucleic acid sequence encoding the α subunit and the nucleic acid sequence encoding the β subunit.

In another embodiment, the present invention relates to a method for preparing nitrile hydratases. The method is characterized in that it is carried out using an expression system according to the invention as described above.

In a preferred embodiment, the method according to the invention is carried out such that the expression is performed at incubation temperatures of less than 30 degrees Celsius, preferably less than 25 degrees Celsius and very particularly preferably at ≤ 20 degrees Celsius. The embodiment in which alcohols, in particular ethanol, are added to the medium, during the expression, at a concentration of less than 10% (w/w), preferably less than 5% (w/w) and very particularly preferably 2-4% (w/w) is also

advantageous. Implementing these measures results in insoluble proteins (inclusion bodies), which do not display any activity, either not being formed, or only being formed to a decreased extent, in the method according to the invention for preparing nitrile hydratases.

In another embodiment, the present invention relates to a host organism which possesses an expression system according to the invention. As already indicated above, the nucleic acid sequences encoding the nitrile hydratase subunits can, in a manner according to the invention as described above, be integrated into plasmids and transformed into host organisms. In addition, and as well as the expression system according to the invention, cloned genes for an amidase which may work stereoselectively (e.g. the amidase disclosed in WO2004/005517 or EP 1318193) may also be present in the host organism. A whole-cell catalyst which has been prepared in this way is advantageously able to produce both the enzymes involved in the nitrile breakdown, thereby ensuring that the nitrile employed is immediately converted into the corresponding carboxylic acid. Whole-cell catalysts which comprise several enzymes which are involved in a reaction cascade have already been disclosed (EP1216304). They are used in the present invention in an equivalent manner. If rhamnose-inducible promoters are used, an organism as specified in DE10155928 should then be employed as the host organism or whole-cell catalyst. It is furthermore advantageous to use an *E. coli* BL21 codon plus which may have been modified in an equivalent manner to that described in DE10155928.

In order to match the expression of the enzymes with regard to their turnover rates, the respective nucleic acid sequences encoding the nitrile hydratase and the amidase can, in accordance with their turnover rates, be cloned in different plasmids having different copy numbers and/or promoters of differing strength in order to obtain differing strengths of expression of the nucleic acid sequences. In

enzyme systems which are matched in this way, there is advantageously no accumulation of an intermediate compound, which may have an inhibitory effect, and the reaction under consideration can take place at an optimal overall rate.

5 However, this is sufficiently well-known to the skilled person (Gellissen, G.; Piontek, M.; Dahlems, U.; Jenzelewski, V.; Gavagan, J.W.; DiCosimo, R.; Anton, D.L.; Janowicz, Z.A. (1996), Recombinant *Hansenula polymorpha* as a biocatalyst. Coexpression of the spinach glycolate oxidase
10 (GO) and the *S. cerevisiae* catalase T (CTT1) gene, Appl. Microbiol. Biotechnol. 46, 46-54; Farwick, M.; London, M.; Dohmen, J.; Dahlems, U.; Gellissen, G.; Strasser, A.W.; DE19920712).

The skilled person is likewise familiar with preparing such
15 whole-cell catalyst (Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York; Balbas, P. and Bolivar, F. (1990), Design and construction of expression plasmid vectors in *E. coli*, Methods Enzymol.
20 185, 14-37; Rodriguez, R.L. and Denhardt, D.T. (eds) (1988), Vectors: a survey of molecular cloning vectors and their uses, 205-225, Butterworth, Stoneham).

Another embodiment of the present invention relates to a
25 method for preparing (amino)carboxylic acids or (amino)carboxamides which may, where appropriate, be enantiomer-enriched. This method is also carried out using a host organism or an expression system as described above. This means that the nitrile hydratases which are involved in
30 the preparation of the carboxylic acids or carboxamides are obtained using a host organism as has just been described. For this application, the enzymes under consideration can be used in free form, as homogeneously purified compounds, or as recombinantly (rec-) prepared enzymes. Furthermore, the
35 enzymes can also be used as components of an intact guest organism or in combination with the disrupted and, if desired, highly purified cell mass of the host organism.

It is likewise possible to use the enzymes in immobilized form (Sharma B.P.; Bailey L.F. and Messing R.A. (1982), Immobilisierte Biomaterialien - Techniken und Anwendungen [Immobilized biomaterials - techniques and applications], Angew. Chem. 94, 836-852). The immobilization is advantageously effected by lyophilization (Paradkar, V.M.; Dordick, J.S. (1994), Aqueous-Like Activity of -Chymotrypsin Dissolved in Nearly Anhydrous Organic Solvents, J. Am. Chem. Soc. 116, 5009-5010; Mori, T.; Okahata, Y. (1997), A variety of lipi-coated glycoside hydrolases as effective glycosyl transfer catalysts in homogeneous organic solvents, Tetrahedron Lett. 38, 1971-1974; Otamiri, M.; Adlercreutz, P.; Matthiasson, B. (1992), Complex formation between chymotrypsin and ethyl cellulose as a means to solubilize the enzyme in active form in toluene, Biocatalysis 6, 291-305). Very particular preference is given to the lyophilization being carried out in the presence of surfactants such as Aerosol OT or polyvinylpyrrolidone or polyethylene glycol (PEG) or Brij 52 (diethylene glycol monocetyl ether) (Kamiya, N.; Okazaki, S.-Y.; Goto, M. (1997), Surfactant-horseradish peroxidase complex catalytically active in anhydrous benzene, Biotechnol. Tech. 11, 375-378).

Extreme preference is given to immobilizing on Eupergit[®], in particular Eupergit C[®] and Eupergit 250L[®] (Röhm) (Eupergit.RTM. C, a carrier for immobilization of enzymes of industrial potential. Katchalski-Katzir, E.; Kraemer, D.M. Journal of Molecular Catalysis B: Enzymatic (2000), 10(1-3), 157-176).

Preference is also given to immobilizing on Ni-NTA in combination with the His tag (hexahistidine)-supplemented polypeptide (Purification of proteins using polyhistidine affinity tags. Bornhorst, Joshua A.; Falke, Joseph J. Methods in Enzymology (2000), 326, 245-254). The use as CLECs is likewise conceivable (St. Clair, N.; Wang, Y.-F.; Margolin, A.L. (2000), Cofactor-bound cross-linked enzyme

crystals (CLEC) of alcohol dehydrogenase, Angew. Chem. Int. Ed. 39, 380-383).

Using these measures, it is possible to generate polypeptides (enzymes) which are stable, and can operate, in mixtures of aqueous and organic solvents, or in organic solvents on their own, from equivalent polypeptides which are rendered unstable by organic solvents.

The following strains are used in the experiments which are described below:

List of the strains employed. (Brandão PFB, Clapp JP and Bull AT (2002). Discrimination and taxonomy of geographically diverse strains of nitrile-metabolising actinomycetes using chemometric and molecular sequencing techniques. Environmental Microbiology 4, 262-276; see also PCT/EP04/00338).

Table 1:

Isolate	DSM	α -subunit Seq. No.	β -subunit Seq. No.
R. erythropolis 870-AN019	15258	1	3
R. erythropolis ENG-AN033	15261	5	7
R. erythropolis 871-AN042	15265	9	11

<i>R. rhodochrous</i> M8	Russian National Collection of Microorganisms VKPM-S-926	13	15
-----------------------------	---	----	----

The following primers were used for the blunt-end cloning in pUC18/19 (xSmaI) (fig. 1) of the nitrile hydratases and the p47K protein (Seq. ID No. 33) from the abovementioned strains:

Primer	Primer sequence	Amplified Subunits	Seq. No.
NH-Re-N	5'-GCC CGC ATA AGA AAA GGT GAA C	α , β , p47K	17
NH-Re-C-p47K	5'-GCA TGC CTT CAA ATC AGC CTC	α , β , p47K	18

The first expression experiments in a one-vector expression system for nitrile hydratases from the *R. erythropolis* strains 870-AN019, 871-AN042 and ENG-AN033 were carried out using plasmids of the pUC18/19 series in different *E. coli* strains. In order to be able to identify the optimal expression host, the pUC18/19 constructs containing the nitrile hydratases from *R. erythropolis* strains 870-AN019, 871-AN042 and ENG-AN033 were transformed into different *E. coli* strains and expressed under the control of the *lac* promoter. The *E. coli* strains in this context were the following: JM109, DM5 α , BL21 codon plus, BL21, HB101, MM294 and XL1blue.

The activities (units per g of dry cell mass) of the recombinant nitrile hydratases in the different hosts can be summarized as follows: it was found that the highest activity was obtained with *E. coli* BL21 codon plus RIL (from Stratagene) in which the copy numbers of the t-RNAs for arginine (AGA/AGG), isoleucine (AUA) and leucine (CUA), which t-RNAs are rare in the case of *E. coli*, are increased.

This host organism was constructed in order, in particular, to express genes having a codon usage which is adapted to a high GC content, for example the genes from *rhodococci* (72% GC).

5

The *R. erythropolis* 870-AN019 nitrile hydratase expressed in *E. coli* BL21 codon plus shows by far the highest activity, of 100 U/g of DBM, with this being followed by 870-AN019 nitrile hydratases expressed in DL5 α (8 U/g of DBM) and
10 ENG-AN033 nitrile hydratases expressed in BL21 codon plus (7 U/g of DBM).

The activities of all the other recombinant organisms were less than 2 U/g of DBM and were undetectable. An activity of 280 U/g of DBM was even achieved for the 870-AN019 nitrile
15 hydratase under optimized conditions.

In that which follows, iron-dependent nitrile hydratases were expressed in a two-vector expression system, with α and β subunits each being present on a separate plasmid. The
20 advantage of this system is that the two units are in each case directly under the control of the T7 promoter, which is employed, where appropriate, and the transcripts for the two genes are consequently formed to equal extents. The p47K helper protein (Seq. ID No. 33) was located downstream of
25 one of the two subunits on a case-by-case basis. Stratagene plasmids of the pET series (pET22b and pET26b) were used as expression vectors. The aim was to express *R. erythropolis* 870-AN019 nitrile hydratase (Seq. Nos. 1 and 3).

30 The following primers were used for cloning the two subunits and the p47K protein (Seq ID No. 33):

Primer	Primer sequence	Amplified orf	Seq. No.
NH019- α -for-Nde	5'-AGG GTC AAC CAT ATG TCA GTA ACG	α	19
NH019- α -rev-Bam	5'-TGT CGG ATC CAT CAG ACG GTG G	α	20
NH019- β -for-Nde	5'-AGC ACC ATA TGG ATG GAG TAC AC	β	21
NH019- β -rev-Eco	5'-GTT GGG AAT TCA GGC CGC AGG	β	22
NH019-p47K-for-Bam	5'-CGC GGA TCC AAG AAG GAG ATA TAC ATG	p47K	23
NH019-p47K-rev-Hind	5'-CCG GAA CGT TCA AAC GGT CTG G	p47K	24

Primers which were derived from the *R. erythropolis* 870-AN019 nitrile hydratase sequence (Brandao PFB, Clapp JP, Bull AT (2003) Diversity of nitrile hydratase and amidase enzyme genes in *Rhodococcus erythropolis* recovered from geographically distinct habitats. Applied and Environmental Microbiology 69(10): 5754-5766; see also PCT/EP04/00338), and which were provided with cleavage sites for the restriction endonucleases *Nde*I (N-terminally) and, respectively, *Bam*HI (α subunit) or *Eco*RI (β subunit) C-terminally, were used for the α and β subunits. The primers for p47K were likewise derived from this organism and contained the cleavage sites for *Bam*HI (N-terminally) and, respectively, *Hin*DIII (C-terminally). The β subunit was cloned into pET26b while the α subunit and p47K were together cloned into pET22b. This resulted in the following plasmids, which were transformed into *E. coli* BL21 codon (+) RIL (see also figs. 2/3).

The activities of the *R. erythropolis* 870-AN019 nitrile hydratase in the *E. coli* strains BL21 and BL21 codon plus RIL (see above) were prepared. When using the above-described expression system, activities of approx. 1750 U/g

of DBM and of 2750 U/g of DBM (based on benzonitrile as substrate) were achieved when using *E. coli* BL21 and *E. coli* BL21 codon (+), respectively. This signifies an increase by a factor of from 5.3 to 8.3 as compared with the one-vector
5 expression systems.

However, it was true that 50% of the recombinant protein in the cell was present, in these experiments, as what are termed inclusion bodies. In order to further improve the
10 activities of the nitrile hydratases, parameters such as IPTG concentration, temperature during the heterologous expression, and the supply of additives to the medium, were investigated. Reducing the IPTG concentration had no effect on the solubility of the recombinant nitrile hydratases. All
15 the subsequent experiments were therefore carried out using 1 mM IPTG. Lowering the incubation temperature had the greatest effect in reducing the formation of inclusion bodies.

By reducing the temperature down to 20°C after the
20 heterologous expression had been induced, it was possible to transfer a large proportion of the enzyme into the soluble fraction. Adding 3% ethanol to the medium had a further positive effect. Under these conditions (1 mM IPTG, 20°C incubation temperature, 3% added ethanol) it was possible to
25 achieve an activity of 6480 U/g of DBM.

A further increase in activity was achieved by using a synthetic 870-AN019 nitrile hydratase gene. The corresponding nucleic acid sequences encoding the α and β subunits were prepared while taking into consideration the
30 *E. coli* codon usage and retaining the amino acid sequences of the two genes. The intended advantage of these synthetic genes was that the DNA sequence would be optimally adapted for expression in *E. coli* and that consequently it would also be possible to dispense with using the "codon plus" strain. The subunits were then separately cloned into pET
35 vectors, as previously described, and expressed in *E. coli* BL21 under the above optimized conditions. Using this

strain, an activity of approx. 10 000 U/g of DBM was achieved. Consequently, this strain is more than twice as active as the wild-type *R. erythropolis* 870-AN019, which has an activity of approx. 4760 U/g of DBM when using benzo-
 5 nitrile as substrate. Table 2 provides a summary of the activities which were achieved.

In the *E. coli* host, the synthetic nitrile hydratase constitutes approx. 50% of the total cell protein formed,
 10 with approx. 20% being present as dissolved recombinant protein.

Table 2: Overview of the nitrile hydratase activities which were measured using different expression systems.

Expression system (Host & promoter)	870-AN019 nitrile hydratase expression conditions		
	Native subunits, standard medium, 26°C	Native subunits, medium + 3% EtOH, 20°C	Synthetic subunits medium + 3% EtOH, 20°C
<i>E. coli</i> BL21 (DE3) + T7 promoter	1750 U/g DBM	-	10080 U/g DBM
<i>E. coli</i> BL21 (DE3) codon usage & T7 promoter	2750 U/g DBM	6480 U/g DBM	-

15

In conclusion, the expression of cobalt-dependent nitrile hydratases was investigated in a two-vector expression system. The cobalt-dependent *Rhodococcus rhodochrous* M8 nitrile hydratase (Pogorelva TE, Ryabchenko LE, Sunzov NI, Yanenko AS (1996) Cobalt-dependent transcription of nitrile
 20 hydratase gene in *Rhodococcus rhodochrous* M8. FEMS Microbiology Letters 144: 191-195) was cloned and prepared using the above-described expression system according to the invention.

The nitrile hydratase sequence (Seq. ID Nos. 13 and 15) is deposited in GenBank (DDBJ, EMBL and NCBI DNA database) under the reference X86737 and is freely available. The following primers were used for cloning the individual subunits and the *R. rhodochrous* M8 p12K protein (Seq. ID No. 31):

Primer	Primer sequence	Amplified subunits	Seq. No.
M8- α -for-Nde	5'-AGG AAT ACG CAT ATG AGC GAGC ACG TC	α	25
M8- α -rev-Bam	5'-GTG TGG ATC CAC TCA TAC GAT CAC TTC CTG	α	26
M8- β -for-Nde	5'-AGG AAT GAG CAT ATG GAT GGT ATC CAC GAC A	β	27
M8- β -rev-Bam	5'-ATC GGG ATC CTT TCA CGC AGA GAT CAG GTA CGG	β	28
M8-p12K-for-Bam	5'-CTC AGG ATC CAA GGA GTG ATC GTA TGA GTG AAG AC	p12K	29
M8-p12K-rev-Sac	5'-ACA GGA GCT CTC AGT CGA TGA TGG CC	p12K	30

Primers which were derived from the M8 nitrile hydratase sequence and which were provided with cleavage sites for the restriction endonucleases *NdeI* (N-terminally) and, respectively, *BamHI* (C-terminally) were used for the α and β subunits. The primers for p12K were derived from the *R. rhodochrous* J1 sequence and contained the cleavage sites for *BamHI* (N-terminally) and, respectively, *SacI* (C-terminally). The β subunit (Seq. ID No. 15) was cloned into pET26b while the α subunit (Seq. ID No. 13) and p12K (Seq. ID No. 31) were cloned into pET22b. This resulted in the following plasmids (figs. 4/5), which were transformed into *E. coli* BL21 codon(+) RIL.

In contrast to the expression of iron-dependent nitrile hydratases in *E. coli*, the cells had, in the case of the

cobalt-dependent nitrile hydratase, to be precultured over several generations in order to accustom to the toxic cobalt (0.5 mM employed).

- 5 Table 3 compares the activities of the recombinant cobalt-dependent (*R. rhodochrous* M8) and iron-dependent (*R. erythropolis* 870-AN019) nitrile hydratases.

10 Table 3: Activities of the cobalt-dependent and iron-dependent nitrile hydratases which were measured, following expression in accordance with the invention, using acrylamide as substrate.

Recombinant nitrile hydratase from	Activity (U/mg); substrate, acrylamide
<i>R. rhodochrous</i> M8 (Co)	160
<i>R. erythropolis</i> 870-AN019 (Fe) (synthetic, see above)	250

15 It was thus possible to demonstrate that the expression system according to the invention can advantageously be used both for cobalt-dependent and for iron-dependent nitrile hydratases. It is possible, in particular, to achieve dramatic increases in activity when the expression systems and/or sequences are appropriately optimized. In addition,
20 as a result of the successful separate expression of the nitrile hydratase subunits, it is possible to investigate novel combinations of subunits belonging to different nitrile hydratases, with this helping to increase the diversification of the nitrile hydratases and consequently
25 the diversification of their properties. At the time of the invention, it was not possible to deduce this, in an obvious manner, from the prior art.

30 Within the context of the invention, "optically enriched (enantiomerically enriched, enantiomer-enriched) compounds" are understood as meaning the presence of one optical

antipode in a mixture with the other at a concentration of
> 50 mol%.

5 The term "nucleic acid sequences" subsumes all types of
single-stranded or double-stranded DNA as well as RNA, or
mixtures thereof.

10 The organisms 870-AN019, ENG-AN033 and 871-AN042 were
deposited by the applicant, on 10.22.2002, in the Deutsche
Sammlung für Mikroorganismen und Zellculkuren [German
collection of microorganisms and cell cultures], Mascheroder
Weg 4, 38124 Braunschweig in accordance with the Budapest
treaty. The organism *Rhodococcus rodochrous* M8 is deposited
15 in the all-Russian national collection of microorganisms
under number VKPM-S-926. The corresponding sequences are
contained in the gene database (see above).

20 According to the invention, the term "expression system" is
understood such that it means nucleic acid-based biological
material which is able, in organisms, to bring about the
expression of the nucleic acid sequences which are inherent
to it and which encode the nitrile hydratase subunits. This
biological material comprises, in particular, plasmids and
vectors.

25 The expressions "protein" and "polypeptide" are used
synonymously within the context of the invention.

Description of the figures:

Figure 1: The vector map shows the general disposition of the nitrile hydratase α and β subunits and, respectively, the p47K orf in the pUC18 plasmid in an expression system using one vector.

Figures 2/3: The vector maps show the disposition of the nitrile hydratase α and β subunits and, respectively, the p47K orf from *R. erythropolis* 870-AN019 in plasmids of the pET series in an expression system using two vectors.

Figures 4/5: The vector maps show the disposition of the α and β subunits and, respectively, the p12K orf from *R. rhodochrous* M8 in plasmids of the pET series in an expression system using two vectors.

Experimental section:

Culturing microorganisms

- 5 The *E. coli* cells are cultured and stored as described in Sambrook et al. (Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), *Molecular cloning: a laboratory manual*, 2nd ed., Cold Spring Harbor Laboratory Press, New York).
- 10 A chelate mineral medium (CMM) as described by Heald et al. 2001 (Heald S.C., P.F.B. Brandao, R. Hardicre and A.T. Bull, 2001: *Physiology, biochemistry and taxonomy of deep-sea nitrile metabolising Rhodococcus strains*. *Antonie van Leeuwenhoek* 80, 169-183) was used for culturing rhodococci.
- 15 The CM medium is supplemented with 5 g of glucose/l. 2.4 mg of $\text{CoCl}_2 \cdot 6 \text{H}_2\text{O}$ /l are used for strains containing cobalt-dependent enzymes while 50 mg of $\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$ /l are used for strains containing iron-dependent enzymes.
- 20 The samples removed from the culture were diluted with potassium phosphate buffer used for the culturing (6 ml of a 200 g/l K_2HPO_4 solution/l and 4 ml of a 157.5 g/l KH_2PO_4 solution/l) such that the measurement range was between 0.05 and 0.3. The buffer served as the reference. Measurements
- 25 were made at 600 nm.

PCR

- For amplifying DNA fragments from rhodococci, the following
- 30 components were pipetted in per 50 μl assay:

- 100 ng of chromosomal DNA
1 μl of dNTP mix (in each case 10 mM)
5 μl of buffer
35 2 μl of DMSO
0.5 μl of herculase (2.5 U)
H₂O to 50 μl

The thermocycler was programmed as follows:

- A. 3 min 98°C
- 5 B. 40 sec 98°C
- C. 40 sec X°C
- D. Y min 72°C
- E. 5 min 72°C
- F. 4°C

10

Steps B, C and D were repeated 30 times. The annealing temperature X (C) is calculated from the melting temperature of the primers employed and the period of incubation Y (D) is calculated from the length of the gene to be amplified
15 (rule, 1 kb of DNA equals 1 minute).

Digesting with restriction enzymes

The DNA to be cut is provided with 5 U of restriction enzyme
20 and the appurtenant buffer and, if nothing else is required, incubated at 37°C. Chromosomal DNA is digested using 10 U of enzyme. The incubation period is from 1.5 to 2.5 hours.

Treating with alkaline phosphatase

25

In order to prevent vectors which have been cut with only one restriction endonuclease from religating with themselves, the protruding phosphate radical at the 5' end is removed with alkaline phosphatase. Circular DNA can only
30 be reformed by inserting a DNA fragment.

The vector which has been cut with a restriction endonuclease is incubated at 65°C for 15 min in order to stop the restriction endonuclease. The dephosphorylation
35 buffer is then added and the mixture is incubated, at 37°C for 10 min, with 1 U of shrimp alkaline phosphatase. The

enzyme is separated off by subsequently subjecting the vector DNA to gel electrophoresis.

Treating with T4 DNA ligase

5

Vector and insert are used for the ligation in a ratio of 1:3. The volume is kept as low as possible (7-20 μ l). The mixture is incubated overnight at 16°C in ligation buffer and in the presence of 1 U of ligase.

10

Transforming

100 μ l of competent cells are pipetted in to the ligation mixture and the whole is mixed by repeatedly drawing up into the pipette. After a 30 min incubation on ice, a heat-shock step is carried out at 42°C for 45 sec and the mixture is incubated on ice for a further 2 min. 120-900 μ l of SOC medium are added and the mixture is incubated at 37°C for 45 min while being shaken. The mixture is subsequently plated out and incubated overnight at 37°C.

20

Expressing the different nitrile hydratases (table 1) in a one-vector expression system

25 The following protocol was used for the expression: 50 ml of LB_{amp100} medium containing 2 mM Fe citrate were inoculated to a concentration of 1% with an overnight culture. After an OD₆₀₀ of approx. 0.5 had been reached, expression of the nitrile hydratases in the different *E. coli* strains was induced with 1 mM IPTG (isopropylthiogalactoside). The cells were harvested approx. 24 hours after induction. The nitrile hydratases were expressed constitutively in strain DH5 α since this strain does not overexpress the *lac* repressor. As a result, the step of inducing with IPTG is dispensed with in the case of this strain.

35

Activity using benzonitrile as substrate:

The biotransformation was carried out on a 10 ml scale using approx. 100 mg of moist biomass ($OD_{600} = 5$) in the potassium phosphate buffer (100 mM) pH 7.0. The incubation took place at 30°C and the substrate concentration was approx. 5 mM benzonitrile. Samples were removed every 5-10 min over a period of at most 1 hour. The sample volume was 100 μ l and the reaction was stopped by adding 10 μ l of 50% phosphoric acid.

The concentrations of benzonitrile and benzamide were then determined by means of HPLC:

Column: RP18 Phenomenex Hypersil ODS 5 μ column (with precolumn)
Mobile phase: 10 mM K_2HPO_4 (pH 2.3)
Flow rate: 1 ml/min
Wavelength: 202 nm
Injection volume: 20 μ l
Duration of HPLC run: 12-15 min

The activity was calculated by calculating a μ mol turnover after one minute, which corresponds to one U (unit). Specific activities are given in U per g of DBM or mg of protein.

Expressing the *R. erythropolis* 870-AN019 nitrile hydratase in a two-vector expression system

The constructs containing T7 promoters were expressed in accordance with the following protocol:
50 ml of LB_{amp100} medium containing 2 mM Fe citrate and in each case 50 μ g of kanamycin and ampicillin/ml were inoculated to a concentration of 1% with an overnight culture. After an OD_{600} of approx. 0.5 had been reached, expression of the nitrile hydratases was induced with 1 mM

IPTG (isopropylthiogalactoside). The cells were harvested approx. 24 hours after inducing at 26°C.

Expressing *R. rhodochrous* M8 nitrile hydratase in a two- 5 vector expression system

The constructs containing T7 promoters were expressed in accordance with the following protocol:
50 ml of LB_{amp100} medium containing 0.5 mM CoCl₂ and in each
10 case 50 µg of kanamycin and ampicillin/ml were inoculated to a concentration of 1% with an overnight culture. After an OD₆₀₀ of approx. 0.5 had been reached, expression of the NHases was induced with 1 mM IPTG (isopropylthiogalactoside). 3% (w/v) ethanol was also added
15 to the medium. The cells were harvested approx. 24 hours after inducing at 26°C.

Determining activity

20 The biotransformation for determining activity using the recombinant *R. rhodochrous* M8 and *R. erythropolis* 870-AN019 nitrile hydratases in *E. coli* took place on a small scale. The biotransformation is carried out in a 1.5 ml Eppendorf cup at 20°C. An OD of 0.4 was used in the biotransformation
25 mixture. 500 µl of a 4% solution of acrylonitrile in 10 mM potassium phosphate buffer, pH 7.5, and also the buffer, are preincubated at 20°C. The reaction is started by adding the cells. The sum of the buffer volume and the cell volume is 500 µl. Immediately after the whole has been mixed, 100 µl
30 are removed and pipetted into 1.5 µl of initially introduced concentrated HCl. After mixing, the sample is centrifuged down at 13 000 rpm for 2 min in an Eppendorf centrifuge and 70 µl of the supernatant are stored at -20°C for HPLC analysis. Samples were removed every 5 - 10 min over a
35 period of at most 2 hours.

Analyzing acrylonitrile, acrylamide and acrylic acid

Using the HPLC method which is described below, it is possible to rapidly analyze acrylonitrile, acrylamide and acrylic acid and to determine the concentrations of these substances:

Column: Synergi 4 μ Hydro-RP with precolumn

Mobile phase: 0.1% H_3PO_4 in 10% acetonitrile, 90% H_2O

10 Flow rate: 0.5 ml/min

Wavelength: 202 nm

Injection volume: 5 μl

Period of HPLC run: 10 min, last peak after 5.5 min

15 The activity was calculated by calculating a μmol turnover after one minute, which corresponds to one U (unit). Specific activities are given in U per g of DBM or mg of protein.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM


Degussa AG

Project House Biotechnology

Rodenbacher Chaussee 4

63457 Hanau-Wolfgang

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>ENG-AN033</u>	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: <u>DSM 15261</u>
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on <u>2002-10-22</u> (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: <u>DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH</u> Address: <u>Mascheroder Weg 1b D-38124 Braunschweig</u>	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <u>2002-10-25</u>


¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa AG
Project House Biotechnology
Rodenbacher Chaussee 4
63457 Hanau-Wolfgang

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: Degussa AG Project House Biotechnology Address: Rodenbacher Chaussee 4 63457 Hanau-Wolfgang		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 15261 Date of the deposit or the transfer ¹ : 2002-10-22	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 2002-10-22 On that date, the said microorganism was <input checked="" type="checkbox"/> ³ viable <input type="checkbox"/> ³ no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-10-25	

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
³ Mark with a cross the applicable box.
⁴ Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM


Degussa AG

Project House Biotechnology

Rodenbacher Chaussee 4

63457 Hanau-Wolfgang

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>871-AN042</u>	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: <u>DSM 15265</u>
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on <u>2002-10-25</u> (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: <u>DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH</u> Address: <u>Mascheroder Weg 1b D-38124 Braunschweig</u>	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <u>2002-10-28</u>

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM


Degussa AG

Project House Biotechnology

Rodenbacher Chaussee 4

63457 Hanau-Wolfgang

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: Degussa AG Project House Biotechnology Address: Rodenbacher Chaussee 4 63457 Hanau-Wolfgang		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 15265 Date of the deposit or the transfer ¹ : 2002-10-25	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 2002-10-25 On that date, the said microorganism was <input checked="" type="checkbox"/> ³ viable <input type="checkbox"/> ³ no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-10-28	

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
³ Mark with a cross the applicable box.
⁴ Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM


Degussa AG

Project House Biotechnology

Rodenbacher Chaussee 4

63457 Hanau-Wolfgang

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: 870-AN019	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 15258
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2002-10-22 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-10-25


¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa AG
Project House Biotechnology
Rodenbacher Chaussee 4
63457 Hanau-Wolfgang

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: Degussa AG Project House Biotechnology Address: Rodenbacher Chaussee 4 63457 Hanau-Wolfgang		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 15258 Date of the deposit or the transfer ¹ : 2002-10-22	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 2002-10-22 ² On that date, the said microorganism was <input checked="" type="checkbox"/> ³ viable <input type="checkbox"/> ³ no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-10-25	

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
³ Mark with a cross the applicable box.
⁴ Fill in if the information has been requested and if the results of the test were negative.

0-1	Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared Using	PCT-SAFE [EASY mode] Version 3.50 (Build 0002.169)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	040065 AM
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	22
1-2	line	8-13
1-3	Identification of deposit	
1-3-1	Name of depositary institution	DSMZ DSMZ-Deutsche Sammlung von Mikroor- ganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	22 October 2002 (22.10.2002)
1-3-4	Accession Number	DSMZ 15261
1-5	Designated States for Which Indications are Made	all designations
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	22
2-2	line	8-13
2-3	Identification of deposit	
2-3-1	Name of depositary institution	DSMZ DSMZ-Deutsche Sammlung von Mikroor- ganismen und Zellkulturen GmbH
2-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
2-3-3	Date of deposit	25 October 2002 (25.10.2002)
2-3-4	Accession Number	DSMZ 15265
2-5	Designated States for Which Indications are Made	all designations
3	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
3-1	page	22
3-2	line	8-13
3-3	Identification of deposit	
3-3-1	Name of depositary institution	DSMZ DSMZ-Deutsche Sammlung von Mikroor- ganismen und Zellkulturen GmbH
3-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
3-3-3	Date of deposit	22 October 2002 (22.10.2002)
3-3-4	Accession Number	DSMZ 15258
3-5	Designated States for Which Indications are Made	all designations

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	yes
0-4-1	Authorized officer	Sabine Albers and

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	25 JULY 2005 (25.07.05)
0-5-1	Authorized officer	Nathalie Wagner